Type:Tablet
Generic Name:Tolterodine Tartrate
Manufacturer:Unimed Unihealth Pharmaceuticals Ltd.
Price:৳2.50
Overactive bladder
Oral Overactive Bladder, Urge Incontinence Immediate release: 2 mg PO q12hr. Reduce to 1 mg bid if needed to reduce side effects. Extended release: 2-4 mg PO once daily Hepatic impairment Mild to moderate (Child-Pugh class A or B): Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release) Severe (Child-Pugh class C): Not recommended
Child < 18 years: Not recommended
Renal impairment CrCl 10-30 mL/min: Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release) CrCl <10 mL/min: Not recommended
Severe ulcerative colitis, toxic megacolon, urinary retention, gastric retention, myasthenia gravis, uncontrolled narrow-angle glaucoma, pregnancy.
Tolterodine is a competitive muscarinic receptor antagonist with actions similar to atropine. It is used in the management of urge urinary incontinence, urgency and frequency.
Bladder flow obstruction, GI obstructive disorders, renal or hepatic impairment, autonomic neuropathy, hiatus hernia, risk of decreased GI motility, patients at risk of QT interval prolongation (e.g. electrolyte disturbances, bradycardia, pre-exisiting cardiac disorder). Lactation: Unknown whether drug is distributed in breast milk; do not nurse
>10% Dry mouth (40%) 1-10% Blurred vision,Constipation,Dizziness,Drowsiness,Dyspepsia,Headache,Xerophthalmia
Increased risk of overdosage with potent CYP3A4 inhibitors e.g. macrolide antibiotics (erythromycin and clarithromycin), azole antifungals (e.g. ketoconazole and itraconazole), protease inhibitors, ciclosporin or vinblastine. Increased risk of torsade de pointes with drugs that prolong the QT interval (e.g. class Ia and class III antiarrhythmics). Increased risk of 'cholinergic neurogenic hypersensitivity' with centrally acting anticholinesterases (e.g. donepezil, rivastigmine). Increased risk of antimuscarinic side effects with antimuscarinic drugs.
